【淋巴癌】《Lantern: LTRN》治療「非何杰金氏淋巴瘤」候選藥物「LP-284」獲准IND

 【淋巴癌】《Lantern: LTRN》治療「非何杰金氏淋巴瘤(NHL)」候選藥物「LP-284」獲准IND

 文章出處  

 Businesswire

 

 原文標題  

Lantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkin’s Lymphomas 

 

 Twitter  

https://twitter.com/aimedadviser/status/1703941672886030363 

 

 文章序號  

4332 

 

智醫科學－AI醫療技術、應用與市場動態

Copyright ©2023 智醫科學 MEDai.tw All rights reserved.

The content of this site is intended for healthcare and medical professionals.